Impact of comorbidities in the response of atopic patients treated with dupilumab: a real‐life study up to 36 weeks
- 26 July 2022
- journal article
- letter
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 36 (12) , E1021-E1023
Abstract
No abstract availableThis publication has 10 references indexed in Scilit:
- Impact of baseline patient characteristics on dupilumab efficacy in type 2 asthmaEuropean Respiratory Journal, 2021
- Dupilumab elicits a favorable response in type-2 inflammatory comorbidities of severe atopic dermatitisClinical and Molecular Allergy, 2021
- Effectiveness and Safety of Long-Term Dupilumab Treatment in Elderly Patients with Atopic Dermatitis: A Multicenter Real-Life Observational StudyAmerican Journal of Clinical Dermatology, 2021
- Dupilumab and conjunctivitis: a case series of twenty patientsJournal of the European Academy of Dermatology and Venereology, 2021
- Efficacy and safety of dupilumab in atopic dermatitis in elderly patients: a retrospective studyClinical and Experimental Dermatology, 2020
- Efficacy of dupilumab in atopic comorbidities associated with moderate‐to‐severe adult atopic dermatitisAllergy, 2020
- Effectiveness and safety of dupilumab for the treatment of atopic dermatitis in adult cohort: a real‐life Italian tertiary centre experienceJournal of the European Academy of Dermatology and Venereology, 2020
- Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trialsThe Lancet, 2019
- Liberty Asthma QUEST: Phase 3 Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate Dupilumab Efficacy/Safety in Patients with Uncontrolled, Moderate-to-Severe AsthmaAdvances in Therapy, 2018
- Guidelines of care for the management of atopic dermatitisJournal of the American Academy of Dermatology, 2014